EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody–Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology

Jung Yoon Jang iD, Donghwan Kim iD, Na Kyeong Lee, Eunok Im iD, Nam Deuk Kim iD

International Journal of Molecular Sciences · 07.07.2025 · 26 (13) · 6523

DOI: 10.3390/ijms26136523 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.07.2025. Verfasst von Jung Yoon Jang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea. Hauptthemen laut MEDLINE: Immunoconjugates, Neoplasms, Camptothecin, Antineoplastic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT), Basic Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) have revolutionized precision oncology by enabling targeted drug delivery with improved therapeutic indices. Among these, deruxtecan (DXd)-based ADCs have demonstrated remarkable efficacy across a range of cancers, particularly in tumors expressing human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), and trophoblast cell surface antigen 2 (TROP2), including breast, lung, gastric, and other solid tumors. DXd, a potent topoisomerase I inhibitor, enhances the cytotoxic potential of ADCs through a cleavable and stable linker and a high drug-to-antibody ratio that ensures optimal drug release. The clinical success of trastuzumab DXd (Enhertu®) and datopotamab DXd (Datroway®), along with the ongoing development of patritumab DXd, has expanded the therapeutic potential of ADCs. However, challenges remain, including toxicity, resistance, and manufacturing scalability. This review discusses the mechanisms of action, clinical progress, and challenges of DXd-based ADCs, highlighting their transformative role in modern oncology and exploring future directions to optimize their efficacy and accessibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesNeoplasmsCamptothecinAntineoplastic AgentsHumansAnimalsTrastuzumab

Stichwörter der Autor:innen

antibody–drug conjugatesanticancerderuxtecantopoisomerase inhibitor

Substanzen

ImmunoconjugatesCamptothecintrastuzumab deruxtecanAntineoplastic AgentsTrastuzumab

Autor:innen und Institutionen

  • Department of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.
  • Functional Food Materials Research Group, Korea Food Research Institute, Wanju-gun 55365, Jeollabuk-do, Republic of Korea.
  • Department of Pharmacy, Eson Geriatric Hospital, Ulsan 44955, Republic of Korea.

ORCID-Profile: Jung Yoon Jang, Donghwan Kim, Eunok Im, Nam Deuk Kim

Förderung

  • Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education
  • National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT)
  • Basic Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education

Zitieren

APA

Jang, J. Y., Kim, D., Lee, N. K., Im, E., & Kim, N. D. (2025). Antibody–Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology. International Journal of Molecular Sciences, 26(13), 6523. https://doi.org/10.3390/ijms26136523

Vancouver

Jang JY, Kim D, Lee NK, Im E, Kim ND. Antibody–Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology. International Journal of Molecular Sciences. 2025;26(13):6523. doi:10.3390/ijms26136523

BibTeX
@article{Jang2025,
  author = {Jang, Jung Yoon and Kim, Donghwan and Lee, Na Kyeong and Im, Eunok and Kim, Nam Deuk},
  title = {Antibody–Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {13},
  pages = {6523},
  doi = {10.3390/ijms26136523}
}
Kostenlos starten →